AstraZeneca Vaccine Fails To Protect Against The South African Variant

Two doses of the AstraZeneca Covid-19 vaccine were found to have only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 South Africa variant, according to a phase 1b-2 clinical trial published on Tuesday in the New England Journal of Medicine.
http://dlvr.it/RvrFy9